HBHaleh Bozorgi

Haleh Bozorgi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Haleh Bozorgi has a total of 24 co-authors. Here are the top co-authors by number of shared publications:

  • Omid Reza Zekavat

    Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    3 shared publications
  • Sezaneh Haghpanah

    Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    3 shared publications
  • Asghar Bazrafshan

    Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    2 shared publications
  • Mohammadreza Bordbar

    Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran

    2 shared publications
  • A. Bazrafshan

    Nemazee Hospital, Hematology Research Center, Shiraz University of Medical Sciences, Shiraz, 71937-1135, Iran

    1 shared publication
  • Ali Amanati

    Professor Alborzi Clinical Microbiology Research Center, Shiraz University of Medical Sciences, Shiraz, Iran.

    1 shared publication

Latest Publications

  • Trace Elements in Children with Acute Lymphoblastic Leukemia

    by Omid Reza Zekavat, Mehran Karimi, Fereshteh Majidi, Mohammadreza Bordbar, Sezaneh Haghpanah, Shirin Parand, Haleh Bozorgi

    Objective: Although combined chemotherapy regimen leads to 80% remission in children with acute lymphocytic leukemia (ALL), malnutrition and altered serum trace elements as a consequence of chemotherapy agents, have become the new issue to deal with. With the aim to evaluate each trace element in childhood ALL, we investiguâtes six main trace elements before and after induction chemotherapy while considering age, gender and chemotherapy protocol as confounding factors. Methods: Thirty-six newly diagnosed ALL children were recruited, and trace elements were assessed by atomic absorption spectrometry technique. Trace elements (Zinc, Copper, Manganese, Magnesium, Chromium and Iron) decreased significantly after induction chemotherapy. Results: Considering the confounding factors, mean difference of elements decreased significantly, except for Chromium. Its mean difference was only significant in children younger than 10 and those who had received standard risk chemotherapy. Conclusion: In conclusion, all the studied trace elements decreased significantly after induction chemotherapy session in ALL children. This highlights the importance of complementary and supplementary management. A larger cohort study with longer follow up is warranted to elucidate the long-term effect of chemotherapy on these trace elements on the general health status, quality of life or risk of relapse in ALL children.


  • Open Access

    Antithrombotic prophylaxis in children and adolescents' patients with SARS-CoV-2 (COVID-19) infection: A practical guidance for clinicians.

    by Mehran Karimi, Haleh Bozorgi, Tahereh Zarei, Mohammadreza Bordbar, Ali Amanati, Arash Safaei, Vincenzo De Sanctis

    Severe coronavirus disease 2019 (COVID-19) is often associated with features of hypercoagulable state which can manifest as venous thromboembolism (VTE) and/or microthrombosis. Given the high risk of VTE in critically ill COVID-19 patients, appropriate VTE prophylaxis seems to be an important part of managing these patients. Although many protocols regarding venous thromboembolism (VTE) prophylaxis or therapeutic (full-dose) anticoagulation have been conducted worldwide, primarily in hospitalised adult patients, details on paediatric patients, if included, are limited or incomplete. The current evidences suggest that anticoagulation therapy with low molecular weight heparins (LMWH) appears to be associated with better prognosis in patients with moderate to severe COVID-19 induced coagulopathies or elevated D-dimer levels. Our recommendations are intended to offer guidance for anticoagulation prophylaxis and treatment in COVID-19 children and adolescent patients and not intend to supersede the clinician judgement. We are also conscious that several clinical questions deserve further studies and clarifications because this area is rapidly evolving.


  • Effect of different iron chelation regimens on bone mass in transfusion-dependent thalassemia patients

    by Mohammadreza Bordbar, Sezaneh Haghpanah, Omid Reza Zekavat, Forough Saki, Asghar Bazrafshan, Haleh Bozorgi

    Objectives: Iron overload might lead to bone loss in transfusion-dependent beta-thalassemia (TDT) patients. To investigate the role of iron chelation therapy (ICT) on bone mineral density (BMD) of TDT patients suffering from iron overload, the authors compared the efficacy of five different iron chelation regimens through assessing serum ferritin and BMD.Methods: In 256 consecutive TDT patients, BMD was measured by dual-energy X-ray absorptiometry in lumbar spine and femoral neck regions. Treatment outcome of five iron chelation regimens including Deferoxamine (DFO), Deferiprone (DFP), Deferasirox (DFX), and combination therapy was evaluated to compare the mean differences of serum ferritin and BMD indices pre- and post-treatment during 12-months follow-up period.Results: No significant difference was observed in DXA characteristics and serum ferritin level changes between ICT groups, but combination of DFO and DFX had the best outcome in improving bone mass through assessing each group individually.Conclusion: Combination therapy with DFX and DFO had the highest impact on reducing serum ferritin, however insignificant, and improving bone loss in both lumbar spine and femoral neck in comparison with other regimens. A randomized prospective clinical trial is advised to accurately assess the efficacy of iron chelation regimens on BMD measurements of TDT patients.


  • Prevalence of endocrine disorders and their associated factors in transfusion-dependent thalassemia patients: a historical cohort study in Southern Iran

    by M. Bordbar, H. Bozorgi, F. Saki, S. Haghpanah, M. Karimi, A. Bazrafshan, O. R. Zekavat

    Transfusion-dependent beta-thalassemia (TDT) patients suffer from various endocrinopathies. The main contributing factor associated with these complications is iron overload, secondary to frequent blood transfusions. To improve patients’ quality of life, we evaluated the prevalence of endocrine disorders while considering the associated factors for further assessment.


  • Comparative effectiveness of alendronate and zoledronic acid on bone mass improvement in transfusion-dependent thalassemia patients

    by Omid Reza Zekavat, Mohamadreza Bordbar, Sezaneh Haghpanah, Forough Saki, Asghar Bazrafshan, Haleh Bozorgi

    Thalassemia, as the most prevalent genetic blood disorder, has many associated comorbidities including low bone mass. We studied the comparative effectiveness of alendronate (AL) and zoledronic acid (ZOL) on bone mass improvement in transfusion-dependent thalassemia (TDT) patients a year after treatment. Three hundred seventy-five TDT patients with low bone mass were enrolled in this study. After a year of treatment with either AL or ZOL, a second bone mineral density (BMD) test was ordered to compare the effectiveness of the two aforementioned drugs. Body mass index (BMI), physical activity, sun exposure, and biochemical laboratory data were also considered as associated factors in this study. The BMD test of both groups was almost the same at the baseline and it increased comparably after a year of treatment with AL and ZOL. However, there was a significant difference in lumbar spine BMD delta Z score between both groups of female patients. ZOL was more effective in increasing the lumbar spine BMD of female patients. The choice of bisphosphonates therapy (oral versus parenteral) should be individually selected by considering patient’s preference, compliance and the physician’s decision. Given the longer administration interval, and TDT patients’ compliance issue, it is justified to recommend ZOL as the drug of choice for patients suffering from low bone mass.